Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Data Compilation #PharmaFlow
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 4-(2-chloro-4-methoxy-5-methylphenyl)-n-((1s)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl)-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine
2. Nbi 74788
3. Nbi-74788
1. Ssr 125543
2. Ssr125543
3. Ssr-125543
4. 752253-39-7
5. Nbi-74788
6. Crinecerfont [usan]
7. 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1s)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine
8. Mft24bx55i
9. 06-rori
10. Chembl291657
11. Chebi:34969
12. Ssr125543a
13. 752253-39-7 (free Base)
14. Chembl1628268
15. (s)-4-(2-chloro-4-methoxy-5-methylphenyl)-n-(2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl)-5-methyl-n-(prop-2-yn-1-yl)thiazol-2-amine
16. Sr-125543a
17. Crinecerfont [inn]
18. Unii-mft24bx55i
19. Gtpl3533
20. Schembl5453205
21. Dtxsid10996687
22. Ssr-125543a
23. Zinc1550164
24. Bdbm50144192
25. Bdbm50348828
26. Pdsp1_000883
27. Pdsp2_000869
28. Who 10958
29. Ncgc00386642-01
30. Hy-106203
31. Cs-0025238
32. Q27088874
33. [4-(4-bromo-phenyl)-5,6-dimethyl-pyrimidin-2-yl]-dicyclopropylmethyl-propyl-amine
34. 2-thiazolamine, 4-(2-chloro-4-methoxy-5-methylphenyl)-n-((1s)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl)-5-methyl-n-2-propynyl-
35. 2-thiazolamine, 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1s)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-2-propyn-1-yl
36. 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-(prop-2-yn-1-yl)-1,3-thiazol-2-amine
| Molecular Weight | 483.0 g/mol |
|---|---|
| Molecular Formula | C27H28ClFN2OS |
| XLogP3 | 8 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 8 |
| Exact Mass | 482.1594906 g/mol |
| Monoisotopic Mass | 482.1594906 g/mol |
| Topological Polar Surface Area | 53.6 Ų |
| Heavy Atom Count | 33 |
| Formal Charge | 0 |
| Complexity | 699 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Treatment of atypical haemolytic uremic syndrome, Treatment of paroxysmal nocturnal haemoglobinuria
Treatment of congenital adrenal hyperplasia
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
STOCK RECAP #PipelineProspector
NEWS #PharmaBuzz
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Crinecerfont manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Crinecerfont, including repackagers and relabelers. The FDA regulates Crinecerfont manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Crinecerfont API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Crinecerfont supplier is an individual or a company that provides Crinecerfont active pharmaceutical ingredient (API) or Crinecerfont finished formulations upon request. The Crinecerfont suppliers may include Crinecerfont API manufacturers, exporters, distributors and traders.
Crinecerfont Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Crinecerfont GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Crinecerfont GMP manufacturer or Crinecerfont GMP API supplier for your needs.
A Crinecerfont CoA (Certificate of Analysis) is a formal document that attests to Crinecerfont's compliance with Crinecerfont specifications and serves as a tool for batch-level quality control.
Crinecerfont CoA mostly includes findings from lab analyses of a specific batch. For each Crinecerfont CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Crinecerfont may be tested according to a variety of international standards, such as European Pharmacopoeia (Crinecerfont EP), Crinecerfont JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Crinecerfont USP).
LOOKING FOR A SUPPLIER?
